The FDA BLA submission is awaiting approval on a priority review .... phase 3 CHF trial is finished awaiting readouts .... phase 3 CLBP trial is finished awaiting readouts ... just to name a few - the current focus on the phase 3 COVID-19 trial for ARDS sufferers cannot change the events listed above or their outcomes - just sayin'
Add to that partnership discussions are ongoing on a number of fronts so IMO what you have posted is dribble !If you are 'so concerned' then perhaps MSB isn't for you ?
MSB appear to not only be walking and chewing gum, but they are blowing bubbles with the gum as well !
Forbes online interview, page-16
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |